论文部分内容阅读
目的观察替米沙坦治疗轻、中度高血压病的临床疗效和安全性。方法将120例轻、中度高血压病人,随机分为治疗组和对照组,治疗组口服替米沙坦40-80mg,每日1次,对照组口服卡托普利25～50mg,每日3次,持续4周。分别观察两组治疗前后血压变化。结果治疗前后两组收缩压(SBP)和舒张压(DBP)均有明显下降,替米沙坦组降压总有效率88.3%,卡托普利组降压总有效率75.0%,两组治疗后降压效果相比有显著性意义(P<0.05)。结论替米沙坦治疗轻、中度原发性高血压疗效确切,安全,可靠,不良反应少。
Objective To observe the clinical efficacy and safety of telmisartan in the treatment of mild to moderate essential hypertension. Methods A total of 120 patients with mild to moderate hypertension were randomly divided into treatment group and control group. The treatment group was treated with telmisartan 40-80 mg once daily and the control group received captopril 25-50 mg daily 3 times for 4 weeks. Two groups were observed before and after treatment of blood pressure changes. Results Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) decreased significantly in both groups before and after treatment. The total effective rate was 88.3% in the telmisartan group and 75.0% in the captopril group. After antihypertensive effect compared with significant (P <0.05). Conclusion Telmisartan treatment of mild to moderate essential hypertension is effective, safe, reliable and less adverse reactions.